New paradigms for BRCA1/BRCA2 testing in women with ovarian cancer:results of the Genetic Testing in Epithelial Ovarian Cancer (GTEOC) study

Plaskocinska, Inga, Shipman, Hannah, Drummond, James, Thompson, Edward, Buchanan, Vanessa, Newcombe, Barbara, Hodgkin, Charlotte, Barter, Elisa, Ridley, Paul, Ng, Rita, Miller, Suzanne, Dann, Adela, Licence, Victoria, Webb, Hayley, Tan, Li Tee, Daly, Margaret, Ayers, Sarah, Rufford, Barnaby, Earl, Helena, Parkinson, Christine, Duncan, Timothy, Jimenez-Linan, Mercedes, Sagoo, Gurdeep S, Abbs, Stephen, Hulbert-Williams, Nicholas, Pharoah, Paul, Crawford, Robin, Brenton, James D and Tischkowitz, Marc (2016) New paradigms for BRCA1/BRCA2 testing in women with ovarian cancer:results of the Genetic Testing in Epithelial Ovarian Cancer (GTEOC) study. Journal of Medical Genetics, 53 (10). pp. 655-661. ISSN 0022-2593

[img]
Preview
PDF (Manuscript) - Published Version
Available under License Creative Commons Attribution Non-commercial.

Download (452kB) | Preview

Abstract

Background: Over recent years genetic testing for germline mutations in BRCA1/BRCA2 has become more readily available because of technological advances and reducing costs.  Objective: To explore the feasibility and acceptability of offering genetic testing to all women recently diagnosed with epithelial ovarian cancer (EOC).  Methods: Between 1 July 2013 and 30 June 2015 women newly diagnosed with EOC were recruited through six sites in East Anglia, UK into the Genetic Testing in Epithelial Ovarian Cancer (GTEOC) study. Eligibility was irrespective of patient age and family history of cancer. The psychosocial arm of the study used self-report, psychometrically validated questionnaires (Depression Anxiety and Stress Scale (DASS-21); Impact of Event Scale (IES)) and cost analysis was performed.  Results: 232 women were recruited and 18 mutations were detected (12 in BRCA1, 6 in BRCA2), giving a mutation yield of 8%, which increased to 12% in unselected women aged <70 years (17/146) but was only 1% in unselected women aged ≥70 years (1/86). IES and DASS-21 scores in response to genetic testing were significantly lower than equivalent scores in response to cancer diagnosis (p<0.001). Correlation tests indicated that although older age is a protective factor against any traumatic impacts of genetic testing, no significant correlation exists between age and distress outcomes.  Conclusions: The mutation yield in unselected women diagnosed with EOC from a heterogeneous population with no founder mutations was 8% in all ages and 12% in women under 70. Unselected genetic testing in women with EOC was acceptable to patients and is potentially less resource-intensive than current standard practice.

Item Type: Article
Additional Information: This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Faculty \ School: Faculty of Medicine and Health Sciences > Norwich Medical School
Depositing User: Pure Connector
Date Deposited: 31 May 2016 15:00
Last Modified: 27 Jul 2020 23:50
URI: https://ueaeprints.uea.ac.uk/id/eprint/59152
DOI: 10.1136/jmedgenet-2016-103902

Actions (login required)

View Item View Item